Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts.

In our exclusive interview, Dr Campos discussed the clinical implications of findings from the gynecologic cancer cohorts of the phase 2 DESTINY-PanTumor02 trial (NCT04482309).